Loading
companiesCompany
FutureChem
FutureChem is a South Korea-based radiopharmaceutical company running 2 late-stage cancer trials of [F-18]Florastamin in prostate cancer.
Overview
FutureChem, based in Seoul, South Korea, is a radiopharmaceutical company. FUTURECHEM is a radiopharmaceutical drug-development company specialising in PET diagnostic imaging agents for neurological and oncological conditions. On ClinicalTrials.gov it is the lead sponsor of 2 recruiting or active phase 2 and phase 3 interventional cancer trials (2 in phase 3), testing [F-18]Florastamin in prostate cancer. The largest, NCT05004285 (Evaluate the Clinical Usefulness of [F-18]Florastamin PET/CT Imaging Diagnosis Compared to MRI Diagnosis), plans to enrol 398 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.
Headquarters
Seoul, KR
Scorecard
All companies#371of 1244 companies, score 10
- phase 3 +3
- targets +2
- modalities +2
- registry trials +3
0 approved, 1 in phase 3, 0 earlier, 1 targets, 2 registry studies. Formula on the scorecards page.
Stage
Public
Website
Phase 3PSMA-targeted PET radiotracer, fluorine-18
Florastamin is FutureChem's fluorine-18 PSMA PET tracer from South Korea, in phase 3 trials for staging high-risk and recurrent prostate cancer alongside the established PSMA agents.
Similar pages
- CompanyForesee Pharmaceuticals
Shares Pivotal (registrational) trial, Clinical trial, Prostate cancer.
- CompanyOakwood Laboratories
Shares Pivotal (registrational) trial, Clinical trial, Prostate cancer.
- TrialStudy of 18F-Florastamin PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer
Shares Florastamin F-18, Prostate cancer.
- CompanyIonis Pharmaceuticals
Shares Pivotal (registrational) trial, Clinical trial, Prostate cancer.
- CompanyPregLem
- CompanyAgennix
- CompanyLisata Therapeutics
- CompanyImmunitor
cancers
fronts
drugs
Phase 3PSMA-targeted PET radiotracer, fluorine-18